Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
862 studies found for:    "Mantle cell lymphoma"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Mantle cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
2 Completed Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: alvocidib;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: pharmacological study
3 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
4 Recruiting Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: DNA analysis;   Other: pharmacological study;   Other: pharmacogenomic studies;   Other: Questionnaire Administration
5 Completed
Has Results 		Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine;   Drug: dexamethasone;   Biological: filgrastim;   Biological: pegfilgrastim;   Procedure: Autologous stem cell transplantation (ASCT)
6 Completed Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Waldenström Macroglobulinemia
Interventions: Drug: vorinostat;   Biological: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis
7 Recruiting Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
8 Active, not recruiting A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Conditions: Mantle Cell Lymphoma;   Lymphoma, Mantle-Cell
Interventions: Drug: Lenalidomide;   Drug: Investigators choice single agent
9 Recruiting Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Conditions: Stage I Mantle Cell Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Biological: Ofatumumab;   Drug: Vincristine Sulfate
10 Active, not recruiting Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma;   Lymphoma, Mantle Cell
Interventions: Drug: EPOCH-R;   Biological: GM-CSF;   Drug: Idiotype vaccine
11 Active, not recruiting EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle Cell;   Mantle Cell Lymphoma
Interventions: Drug: Rituximab (R);   Biological: EPOCH;   Drug: Bortezomib (B);   Drug: Bortezomib;   Drug: Bortezomib or observation
12 Not yet recruiting Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Conditions: Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab
13 Completed Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Rituximab;   Drug: Zevalin
14 Active, not recruiting Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Temsirolimus
15 Active, not recruiting Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Condition: Mantle Cell Lymphoma
Intervention: Drug: lenalidomide, bendamustine, rituximab
16 Terminated Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: ZARNESTRA (Tipifarnib)
17 Completed Study of Mantle Cell Lymphoma Treatment by RiBVD
Condition: Mantle Cell Lymphoma
Intervention: Drug: RiBVD
18 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   Non-hodgkin Lymphoma,B Cell;   Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
19 Active, not recruiting Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: lenalidomide;   Biological: rituximab
20 Completed Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
Condition: Mantle Cell Lymphoma
Interventions: Drug: Adriblastin;   Drug: dexamethasone;   Drug: Chlorambucil;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: alkeran;   Procedure: Total body irradiation (8Gy/4fr);   Drug: vincristine
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years